Biotech Values

[DewDiligence]

AMRI licenses CRISPR-Cas9 technology for undisclosed client projects:

http://finance.yahoo.com/news/amri-licenses-crispr-cas9-gene-200500622.html

AMRI today announced that it entered into a non-exclusive commercial license agreement with the Broad Institute of MIT and Harvard for the use of CRISPR-Cas9 gene editing technology… Financial terms were not disclosed.

Under the terms of the commercial use license, AMRI gained access to IP related to CRISPR-Cas9 technology that is being used to enhance AMRI's drug discovery services offerings and associated client programs. The application of CRISPR-Cas9 technology benefits a number of the specific services that AMRI provides to its customers, including protein production, cell line and assay development, high content screening and analysis, and target validation and assessment.